An mRNA COVID-19 booster after viral vector vaccine jabs may cut infection risk by half

Embargoed until: Publicly released: 2022-02-10 09:00

International

Janssen_COVID-19_vaccine_(2021)_J By Agência Brasília - CC BY 2.0

A study of nearly 26,000 US veterans who had received two doses of the Johnson & Johnson (Jansen) COVID-19 vaccine (a viral vector vaccine) found those who received an mRNA booster (either Pfizer or Moderna) cut their chances of subsequent COVID-19 infection by half, compared with those whose booster was also Johnson & Johnson. But for those whose first two doses were an mRNA vaccine, having a different mRNA jab as a booster did not affect their chances of catching COVID-19.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research Massachusetts Medical Society, Web page The URL will go live after the embargo ends

Journal/
conference: New England Journal of Medicine

Research:Paper

Organisation/s: Veterans Affairs Pittsburgh Healthcare System, USA

Funder: upported by the facilities of the Veterans Affairs Shared Data Resource; by the resources and facilities of the Department of Veterans Affairs Informatics and Computing Infrastructure (VA HSR RES 13-457); and by the resources and facilities of the Veterans Affairs Pittsburgh Healthcare System and the central data repositories maintained by the Veterans Affairs Information Resource Center, including the Corporate Data Warehouse. Dr. Mayr is supported by a grant (K23GM132688) from the National Institutes of Health.

Media Contact/s

Contact details are only visible to registered journalists.